M
Mingbo Su
Researcher at Chinese Academy of Sciences
Publications - 55
Citations - 946
Mingbo Su is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Histone deacetylase & Hydroxamic acid. The author has an hindex of 15, co-authored 52 publications receiving 768 citations. Previous affiliations of Mingbo Su include Nanjing University of Chinese Medicine.
Papers
More filters
Journal ArticleDOI
Small Molecule Antagonizes Autoinhibition and Activates AMP-activated Protein Kinase in Cells
Tao Pang,Zhen-Shan Zhang,Min Gu,Bei-Ying Qiu,Li-Fang Yu,Peng-Rong Cao,Wei Shao,Mingbo Su,Jing-Ya Li,Fajun Nan,Jia Li +10 more
TL;DR: PT1 highlights the effort to discover novel AMPK activators and can be a useful tool for elucidating the mechanism responsible for conformational change and autoinhibitory regulation of AMPK.
Journal ArticleDOI
Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Xuan Zhang,Yannan Kong,Jie Zhang,Mingbo Su,Yubo Zhou,Yi Zang,Jia Li,Yi Chen,Yanfen Fang,Xiongwen Zhang,Wei Lu +10 more
TL;DR: A new class of colchicine derivatives were designed and synthesized as tubulin-HDAC dual inhibitors, which exhibited powerful tubulin inhibitory activity, moderate anti- HDAC activity and the most potent cytotoxicity.
Journal ArticleDOI
Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators
Li-Fang Yu,Yuan-Yuan Li,Mingbo Su,Zhang Mei,Wei Zhang,Lina Zhang,Tao Pang,Run-Tao Zhang,Bing Liu,Jing-Ya Li,Jia Li,Fajun Nan +11 more
TL;DR: In the diet-induced obesity mouse model, compound 24 was found to improve glucose tolerance and alleviate insulin resistance and the in vitro and in vivo data for these alkene oxindoles warrant further studies for their potential therapeutic medications in metabolic associated diseases.
Journal ArticleDOI
The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
TL;DR: A novel class of colchicine-SAHA hybrids were designed and synthesised based on the synergistic antitumor effect of tubulin inhibitors and histone deacetylases (HDAC) inhibitors, which is the first design of molecules that are dual inhibitors of Tubulin and HDAC.
Journal ArticleDOI
Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice.
Yuan-Yuan Li,Li-Fang Yu,Lina Zhang,Bei-Ying Qiu,Mingbo Su,Fang Wu,Dakai Chen,Tao Pang,Min Gu,Wei Zhang,Wei-Ping Ma,Haowen Jiang,Jing-Ya Li,Fajun Nan,Jia Li +14 more
TL;DR: Chronic oral treatment with multiple doses of C24 significantly reduced blood glucose and lipid levels in plasma, and improved the glucose tolerance of diabetic db/db mice, demonstrating that this orally effective activator of AMPK represents a novel approach to the treatment of metabolic syndrome.